title: Medtronic CoreValve Evolut valve.
abstract: The first member of the next generation CoreValve "family" is the 23 mm CoreValve® Evolut™ (Medtronic, Minneapolis, MN, USA), which is indicated for an annulus range of 18 mm to 20 mm and extends the spectrum of patients with aortic stenosis that can be treated with the self-expanding CoreValve bioprosthesis. The Core-Valve Evolut provides several technical refinements and is designed to enable re-capturability in the future. Here, we report on the first case in a 93-year-old female patient who was implanted at the University Hospital Bonn, Germany, on June 1st, 2012.
authors.affiliation: Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany.
authors.forename: Jan-Malte
authors.initials: JM
authors.lastname: Sinning
authors.forename: Nikos
authors.initials: N
authors.lastname: Werner
authors.forename: Georg
authors.initials: G
authors.lastname: Nickenig
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
mesh_terms: D000369:Aged, 80 and over; D001022:Aortic Valve Insufficiency / Q000209:etiology / Q000517:prevention & control; D001024:Aortic Valve Stenosis / Q000503:physiopathology / Q000628:therapy*; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000295:instrumentation*; D019317:Evidence-Based Medicine; D005260:Female; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D006439:Hemodynamics; D006801:Humans; D018579:Patient Selection; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome